GlassScriptPhysician profile
Olivia Wasco
NPI 1144867946
$1,279.52
in general payments reported to CMS, 2019-2025
23 companies · $1,041 in 2025
The $1,041 reported for 2025 was more than what 84% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $239 · 2025: $1,041.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,200 · Education: $79.94.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,199.58 |
| Education | $79.94 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $214.52 | 2024-2025 | Airsupra, Tezspire, Farxiga |
| Regeneron Healthcare Solutions, INC. | $100.64 | 2024-2025 | Dupixent |
| Pfizer INC. | $99.11 | 2024-2025 | |
| Genzyme Corporation | $95.08 | 2024-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $88.08 | 2025 | |
| Sumitomo Pharma America, INC. | $77.32 | 2025 | Gemtesa |
| Glaxosmithkline, LLC. | $73.01 | 2025 | Nucala, Trelegy Ellipta, Arexvy |
| Merck Sharp & Dohme LLC | $48.61 | 2024-2025 | Winrevair |
| Axsome Therapeutics, INC. | $46.65 | 2025 | Auvelity |
| Boehringer Ingelheim Pharmaceuticals, INC. | $44.41 | 2025 | Ofev, Jardiance |
| United Therapeutics Corporation | $44.16 | 2025 | Tyvaso |
| Shield Therapeutics INC | $38.92 | 2025 | |
| Viatris Specialty LLC | $38.48 | 2025 | Yupelri |
| Amgen INC. | $37.96 | 2025 | Tezspire |
| Abbvie INC. | $34.50 | 2024-2025 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Corcept Therapeutics | $33.20 | 2025 | Korlym |
| Corium, LLC | $31.00 | 2025 | Azstarys |
| Novo Nordisk INC | $30.12 | 2025 | Ozempic, Wegovy |
| Actelion Pharmaceuticals US, INC. | $27.89 | 2024 | Uptravi, Opsumit |
| Takeda Pharmaceuticals U.S.A., INC. | $23.76 | 2025 | Glassia |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $21.74 | 2025 | Xifaxan |
| Verona Pharma, INC. | $15.96 | 2025 | Ohtuvayre |
| Abbott Laboratories | $14.40 | 2025 | Freestyle Libre 3 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Olivia Wasco listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.